Private Equity-Backed Crealta Makes Its First Move With Savient Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.